PEGylation has proven to be a valuable tool to prolong the half-life of proteins in drug delivery. Covalent binding of one or more polyethylene glycol (PEG) molecules-either with the attachment of small (5-10 kDa) PEG groups, or site-directed attachment of large (≤60 kDa) PEG molecules via linkers-increases the hydrodynamic radius of a protein, improving drug stability and reducing clearance receptor interaction. 1,2 At least 12 PEGylated biopharmaceuticals have been approved in Europe and the United States, across multiple indications. PEGylated products have a clinical track record of >20 years, and no long-term PEG-related safety signals have been identified in humans. Most of the approved products are used to treat chronic diseases, including hepatitis, immunodeficiency disorders, renal failure and autoimmune diseases. 1 Short-term effects of PEG immunogenicity on safety, by detection of either pre-existing or PEGylated biologic-induced anti-PEG IgM and IgG antibodies, have been reported, but will not be the focus of this letter.
Improved pharmacokinetics (PK) and pharmacodynamics con- Table 1 ). 3 The resulting half-life prolongation is substantially higher for FIX compared with FVIII products.
Polyethylene glycol molecules have a simple, repetitive structure and are chemically inert, with low toxicity. They are uncharged, water-soluble, non-reactive and do not have any specific receptors or targets in the body. 1, 4 However, the accumulation of large (>20-30 kDa) PEG molecules in renal tubular and choroid plexus epithelial cells is a concern because of their increasingly reduced clearance with higher molecular size. 4 In addition, cellular vacuolation in certain tissues and cell types has been observed in non-clinical toxicology studies for about half the PEGylated biologics. 4, 5 How can we address these concerns when discussing PEGylated distortion. 4 In the absence of changes in cell morphology, or changes in surrounding tissue, cellular vacuolation observed with high PEG doses has not been linked to changes in organ function and is therefore not considered adverse. Nor have there been any reports of PEG-related adverse events with PEGylated drugs in humans. Although no changes in physiology or function have been reported, it remains unknown whether vacuoles caused by more prolonged or lifelong exposure to higher molecular weight PEG may have functional consequences. 4 One major concern is the possible long-term effect of PEG with chronic administration of PEGylated biologics. These risks are assessed by chronic toxicology studies.
Usually, an immune response is observed when running toxicology studies with a human protein in experimental animals, thereby limiting the possibility to address concerns associated with the long-term use of such products. In order to overcome this situation, immunodeficient athymic rats have been used to evaluate PEGylated biologics in addition to existing toxicology programmes. 7, 8 In such studies, possible long-term effects of the PEGylated product can be investigated without interference by the immune system, and thus, a more relevant risk assessment for chronic effects can be performed.
In a recent study with damoctocog alfa pegol, no vacuolation was detected in immunodeficient rats after chronic administration up to 26 weeks. 8 This was likely because of the low doses used (still up to 30 × higher than the human dose) reflecting the low dose-ranges needed for therapeutic efficacy of FVIII products. In recent rat studies, it was proposed that PEG-40 blood concentrations >100 µg/mL may trigger tissue vacuolation. 9 This is 1000-fold higher than concentrations observed in clinical studies with damoctocog alfa pegol (60 kDa PEG blood concentration: maximum 0.1 µg/mL). 2 Understanding PK, metabolism and biodistribution of PEGylated proteins is important for drug safety. PK properties of PEGylated proteins are initially driven by the two major parts of the molecule: the protein itself and its conjugated PEG. When PEG remains after protein catabolism, its biodistribution and PK properties are governed by PEG-related mechanisms. The primary excretion mechanism for PEG molecules up to 60 kDa is urinary. The rate of cellular uptake and excretion is determined by PEG size, PEGylated protein characteristics, existing non-specific uptake or receptor-mediated cellular uptake, PEG dose and dosing frequency, and turnover kinetics of the cells involved in PEG uptake. 5 Due to the low clearance of PEG, its concentration in blood and tissue levels rises until a steady state is reached. Since excretion processes have been demonstrated, including for large PEGs up to 60 kDa, once a steady state is reached, there are no further increases in blood and/or tissue concentrations. 2 doses and the expected plasma, organ and tissue exposures were considerably higher than for PEG-60 from damoctocog alfa pegol. In conclusion, the long-term safety risks of PEGylated biologics must be individually investigated using the described strategy.
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